Group 1: Company Strategy and Market Position - The company has successfully adjusted its strategy in response to the national drug centralized procurement, leading to a gradual recovery in sales of contrast agents, with a steady growth trend [1][2]. - The company aims to expand its market share by actively participating in centralized procurement while enhancing marketing efforts in non-procurement markets [3]. - The approval of Gadobutrol injection in July 2024 and its subsequent inclusion in the national centralized procurement is expected to enhance the company's market presence [2]. Group 2: Product Development and R&D Progress - The company has diversified its gadolinium-based contrast agents, now offering four MRI contrast agents, which helps meet various clinical needs and enhances market competitiveness [1][2]. - Recent approvals include Gadobutrol and other formulations, with ongoing evaluations for multiple products that target significant therapeutic areas [6][7]. - The company is focusing on integrating R&D resources and improving efficiency to support its strategic expansion in various therapeutic fields [6]. Group 3: International Market Expansion - The company achieved overseas revenue of 132.16 million yuan in 2024, marking a 15.02% increase year-on-year, with products successfully entering markets in South America, Africa, and Asia [4]. - The completion of EU GMP and Brazil ANVISA GMP certifications is expected to accelerate the internationalization of the company's contrast agents [4]. Group 4: Financial Performance and Future Outlook - The company anticipates further revenue growth from the upcoming centralized procurement of Gadobutrol and Gadobenate dimeglumine, which are expected to enhance brand influence [2][3]. - The company is also exploring opportunities in the overseas market, particularly in the EU, where several products have received registration [4]. Group 5: Subsidiary and Partner Developments - The acquisition of Tianyuan Pharmaceutical has led to successful integration into the group management system, focusing on enhancing operational efficiency across various departments [10]. - Recent advancements by partners, such as the launch of innovative cancer screening technologies by Shihe Gene, indicate a positive trend in the healthcare sector [11][12].

Group 1: Financial Performance - The company achieved a turnaround in 2024, primarily due to product structure optimization and increased marketing efforts, leading to stable revenue growth in the chemical drug sector [1] - The acquisition of 80% of Tianyuan Pharmaceutical contributed to revenue growth in the traditional Chinese medicine segment [1] - The company managed to reduce R&D investment compared to 2023 while maintaining a high level of overall R&D input [1][2] Group 2: R&D Strategy - In 2025, the R&D focus will be on chemical drugs, traditional Chinese medicine, and the health sector, aiming for technological innovation and market expansion [3] - The company received approval for "Silicone Oil Emulsion" and "Compound Polyethylene Glycol Electrolyte Powder (III)" in February 2025, enhancing its product pipeline in the digestive system field [3] - A strategic partnership with Anhui Chengqing Tang National Medicine Co., Ltd. aims to modernize traditional Chinese medicine production [3] Group 3: Subsidiary Operations - Shenzhen Yiwei Medical Technology Co., Ltd., a subsidiary, specializes in early screening, precise diagnosis, and rehabilitation for brain diseases, recognized as a national "little giant" enterprise [4] - Yiwei Medical's core products address stroke, Alzheimer's disease, cognitive disorders, and developmental disabilities, providing comprehensive solutions in the brain disease sector [5] Group 4: Business Model - Yiwei Medical offers a full-service model from screening to rehabilitation, creating a closed-loop medical service system [6] - The company collaborates with health check institutions to provide a comprehensive "brain routine" health check package [6] Group 5: International Expansion - The company has made significant progress in overseas markets, achieving full product line sales of contrast agents and obtaining EU GMP and Brazil ANVISA GMP certifications for its production line [7][8] - The company is accelerating the registration of contrast agent products for international markets, laying the groundwork for broader market expansion [8] Group 6: Acquisition Strategy - Recent acquisitions, such as Haichang Pharmaceutical and Tianyuan Pharmaceutical, have strengthened the company's competitive position in the contrast agent and traditional Chinese medicine markets [9] - Future acquisitions will align with the company's overall strategic development and business growth needs, adhering to regulatory requirements [9]